TOVXTheriva Biologics Inc. Common Stock

0.2350USD+4.26%Mkt Cap: 10.78M $P/E: 0.16

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepve…

Key Statistics

Company
Market Cap10.78M $
Enterprise Value3.00M $
Revenue (TTM)300.00K $
Gross Profit300.00K $
Net Income (TTM)-23.74M $
Revenue/Share0.0100 USD
Last Price0.2350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)0.16
P/E (Forward)-1.18
PEG
EV/EBITDA-0.25
EV/Revenue10.00
P/S35.95
P/B0.88
EPS (TTM)1.44
EPS (Forward)-0.20
52W Range
0.160011% of range0.8600
52W High0.8600 USD
52W Low0.1600 USD
Profitability
Gross Margin100.00%
Oper. Margin-4022.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-154.32%
ROA-62.08%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-16.67M $
CapEx (TTM)35.00K $
FCF Margin-2231.42%
FCF Yield-62.07%
Net Debt-7.78M $
Net Debt/EBITDA0.65
Balance Sheet
Debt/Equity0.17
Current Ratio1.13
Quick Ratio1.08
Book Value/Sh0.2660 USD
Cash/Share0.2470 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateAug 13, 2018
Splits
Last Split1:25
Split DateAug 26, 2024
Analyst Consensus
Rating
Target (Mean)2.500 USD
Upside (mean)+963.8%
Target Range1.000 USD4.000 USD
$1.000+963.8% to mean$4.000
# Analysts2
Ownership
Shares Out.45.89M
Float45.14M
Insiders1.63%
Institutions4.35%
Short Interest
Short Ratio0.9d
Short % Float4.61%
Short % Out.4.61%
Shares Short2.12M
Short (prev mo.)1.45M
Technical
SMA 500.2392 (-1.8%)
SMA 2000.2410 (-2.5%)
Beta1.12
S&P 52W Chg19.18%
Avg Vol (30d)536.93K
Avg Vol (10d)602.46K
Technical Indicators
RSI (14)51.6
MACD-0.0019
MACD Signal-0.0044
MACD Hist.+0.0025
BB Upper0.2416 USD
BB Middle0.2242 USD
BB Lower0.2069 USD
BB Width15.48%
ATR (14)0.0153 USD
Vol Ratio (20d)0.99x